Bristol-Myers Squibb (BMY)

AI-powered earnings call analysis for Bristol-Myers Squibb. Get insights from quarterly earnings reports with our AI-generated podcast. Educational content only - not investment advice.

15 episodes 5 languages

Next Episode

Bristol-Myers Squibb earnings call scheduled for Oct 29, 2026 (before market open)

New episode expected Oct 30, 2026

Latest Episode

Q2 2026 Earnings

6:51 • 7/31/2026

Bristol-Myers Squibb (BMY) - Q2 2026

0:00

6:51

Speed:

Q2 2026 Earnings

8:40 • 2026/7/31

Bristol-Myers Squibb (BMY) - Q2 2026

0:00

8:40

Speed:

Q2 2026 Earnings

9:24 • 31/07/2026

Bristol-Myers Squibb (BMY) - Q2 2026

0:00

9:24

Speed:

Q2 2026 Earnings

9:09 • 31/7/2026

Bristol-Myers Squibb (BMY) - Q2 2026

0:00

9:09

Speed:

Q2 2026 Earnings

8:32 • 31.7.2026

Bristol-Myers Squibb (BMY) - Q2 2026

0:00

8:32

Speed:

All Episodes

EN - English (3) CN - 中文 (3) FR - Français (3) ES - Español (3) DE - Deutsch (3)

Q2 2026 Earnings

6:51

Bristol-Myers Squibb delivered strong Q2 with $13B revenue (+5%) driven by growth portfolio reaching 60% of sales (+14%), while raising 2026 guidance and advancing pipeline toward 10+ new medicines by decade end.

Q1 2026 Earnings

7:45

Bristol-Myers Squibb delivered solid Q1 2026 with $11.5B revenue (+1% YoY) and growth portfolio sales of $6.2B (+9%), driven by Eliquis and cell therapy, while advancing a diversified pipeline with multiple late-stage catalysts expected in late 2026.